Revised SPC: Cometriq (cabozantinib) 20 mg Hard Capsules

SPC updated to explain that while Cabometyx and Cometriq have same active ingredient, they are not bioequivalent, and to include warnings relating to GI events and posterior reversible encephalopathy syndrome, as well as additional warnings relating to thromboembolic events.

Source:

electronic Medicines compendium